Aracê.
September 29, 2026
Renato Lemes Peixoto, Lígia Freitas
A Ayahuasca é uma preparação de origem amazônica tradicionalmente produzida a partir da combinação de Banisteriopsis caapi e Psychotria viridis, contendo compostos biologicamente ativos como N,N-dimetiltriptamina (DMT), harmina, harmalina e tetrahidroharmina. Nas últimas décadas, sua utilização ultrapassou os contextos tradicionais e religiosos amazônicos, alcançando centros urbanos e...
The International Journal of Neuropsychopharmacology
September 9, 2026
R Freire, C Chaves, M Cabo et al.
Abstract Background Anxiety disorders are among the most prevalent psychiatric disorders worldwide, causing significant impacts on physical and emotional health and substantial functional impairment. Not only individuals with anxiety disorders have severe and debilitating anxiety symptoms; patients with PTSD, OCD and mood disorders often present with anxiety. The term classic psychedelics...
Harvard Review of Psychiatry
September 8, 2026
Warwick M. Green, Sanket B Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
Zenodo (CERN European Organization for Nuclear Research)
September 7, 2026
Flávio Marco Rego da Silva
preprint
Rationale: Increased neural complexity under psychedelics is replicated, but the temporal structure carrying it — and the design choices that decide what a "complexity increase" means — remain contested: window-level reports treat correlated windows as independent; cross-dataset contrasts confound pharmacology with protocol. Objectives: To test, in public EEG datasets with pre-registered...
Human Psychopharmacology: Clinical and Experimental
September 1, 2026
José Norberto Vásquez-Bonilla
OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...
Clinical Neuropsychopharmacology and Addiction
September 1, 2026
Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.
Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...
International Journal of Innovative Technologies in Social Science
August 31, 2026
Katarzyna Pawłucka, Aleksandra Pawlucka, Joanna Kadłuczka et al.
Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine. Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR...
Pharmacological Research
August 26, 2026
Mattia Giovenzana, Noemi Nicosia, Stefano Spinosa et al.
Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral...
Zenodo (CERN European Organization for Nuclear Research)
August 21, 2026
Ivan Temprado-Ordiaz
preprint
3,4-Methylenedioxymethamphetamine (MDMA) has emerged as a promising therapeutic candidate for treatment-resistant neuropathic pain, offering a paradigm shift from transient palliative symptom masking toward disease-modifying neuroplastic reorganization. Preclinical and clinical evidence demonstrates that MDMA operates through an integrated, multi-tiered neurobiological cascade: presynaptic...
Life
August 14, 2026
Szabolcs Kéri
Clinical trials and naturalistic studies describe psychedelics under markedly different exposure conditions. This narrative review searched PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, and regulatory sources through 15 July 2026, and examined safety and outcomes across four dimensions of exposure: dose, frequency, person, and context. In screened adults receiving one to three...